Biomanufacturers are in a unique and difficult position as they need highly specific critical raw materials, in comparatively small quantities, for life-saving therapies.
However, there is no industry consensus on a strategic view of how the supply chain and demand will evolve in the next five years or more. This poses a significant risk to patients and healthcare providers, e.g., through drug shortages and price increases.
This paper summarizes the industry position and aims to start a strategic discussion on this situation. It will help ensure we have a common language and understanding across industry. Looking ahead, we will emphasize shared learning, best practices, and retrospective investigations to improve long-range planning processes.
Call to action
To do all of this, we are expanding our team to include those with knowledge of long-range planning processes. Are you involved in strategic network planning, strategic development (supply and demand), supply chain strategic planning, sourcing or procurement? Then the Long-Range Planning Workstream could be for you.
If you want to share your knowledge and learn from other world-leading experts and help develop a best-in-class supply chain for the biopharmaceutical industry, then contact Ciera Clayton on firstname.lastname@example.org